The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical experience with an inactivated hepatitis A vaccine.
Abstract
Clinical trials of an inactivated hepatitis A vaccine have encompassed 104 studies completed by December 1993 in 27 countries. Studies involved 50,677 subjects and administration of > 120,000 vaccine doses. Results show that the vaccine is safe, clinically well-tolerated, and highly immunogenic in all age groups. A seroconversion rate of 100% is achieved 1 month after primary vaccination. Vaccine-induced antibody titers persist after a primary vaccination course for > or = 1 year with a single dose of 1440 ELISA units (EL.U.) in adults and after two doses of 360 EL.U. in children. A booster dose 6-12 months after the first vaccine dose induces very high antibody titers, which according to a mathematical model, are expected to protect against hepatitis A for > 20 years. The vaccine is equally immunogenic when administered simultaneously with other traveler vaccines, therefore enabling flexible and convenient vaccination against hepatitis A.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By 1 month after the first dose, 94%–100% of adults have protective antibody levels, and after a second dose, 100% achieve protective levels (1297,1300,1301).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1300]
Citations
Cites
Protection Against Hepatitis A by an Inactivated Vaccine
Innis, B. L. (1994) · JAMA · doi:10.1001/jama.1994.03510410040030 · Cited by 459
Epidemiological patterns of hepatitis A in different parts of the world
Gust, I. D. (1992) · Vaccine · doi:10.1016/0264-410x(92)90544-t · Cited by 172
Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long‐term antibody persistence
Damme, P. V., Thoelen, S., Cramm, M., Groote, K. D., Safary, A., & Meheus, A. (1994) · Journal of Medical Virology · doi:10.1002/jmv.1890440425 · Cited by 158
André, F. E., d'Hondt, E., Delem, A., & Safary, A. (1992) · Vaccine · doi:10.1016/0264-410x(92)90576-6 · Cited by 150
Serum Neutralizing Antibody Response to Hepatitis A Virus
Lemon, S. M., & Binn, L. N. (1983) · The Journal of Infectious Diseases · doi:10.1093/infdis/148.6.1033 · Cited by 140
Immunoglobulin prophylaxis for hepatitis A.
Winokur, P. L., & Stapleton, J. T. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.2.580 · Cited by 136 · cited 1×
“Although immune serum globulin (ISG) offers effective passive protection (~-85%) against hepatitis A for travelers [9], patient compliance is low because of a number of factors including lack of information on availability, its cost, injection site pain, and the fact that immunoglobulins are bloodderived products.”
BackgroundInactivated candidate vaccines for hepatitis A.
André, F. E., Hepburn, A., & d'Hondt, E. (1990) · PubMed · Cited by 106
Heß, G., Clemens, R. L., Bienzle, U., Schönfeld, C., Schunck, B., & Bock, H. (1995) · Journal of Medical Virology · doi:10.1002/jmv.1890460109 · Cited by 94
Interruption of an outbreak of hepatitis A in two villages by vaccination
Prikazský, V., Oleár, V., Cernoch, A., Safary, A., & André, F. E. (1994) · Journal of Medical Virology · doi:10.1002/jmv.1890440427 · Cited by 93
Production, quality control and characterization of an inactivated hepatitis A vaccine
Peetermans, J. (1992) · Vaccine · doi:10.1016/0264-410x(92)90557-z · Cited by 83
Simultaneous passive and active immunization against hepatitis A
Leentvaar-Kuijpers, A., Coutinho, R. A., Brulein, V., & Safary, A. (1992) · Vaccine · doi:10.1016/0264-410x(92)90569-6 · Cited by 60
Woodson, R. D. (1969) · JAMA · doi:10.1001/jama.1969.03160200017004 · Cited by 58
Simultaneous vaccination against hepatitis A and B: results of a controlled study
Ambrosch, F., André, F. E., Delem, A., D'Hondt, E., Jonas, S., Kunz, C., Safary, A., & Wiedermann, G. (1992) · Vaccine · doi:10.1016/0264-410x(92)90570-a · Cited by 56
Hepatitis A in the US Army: epidemiology and vaccine development
Hoke, C. H., Binn, L. N., Egan, J. E., DeFraites, R. F., Macarthy, P., Innis, B. L., Eckels, K. H., Dubois, D. R., d'Hondt, E., Sjögren, M. H., et al. (1992) · Vaccine · doi:10.1016/0264-410x(92)90550-4 · Cited by 42
Westblom, T. U., Gudipati, S., DeRousse, C., Midkiff, B. R., & Belshe, R. B. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.5.996 · Cited by 40
Goubau, P., Gerven, V. V., Safary, A., Delem, A., Bande-Knops, J., d'Hondt, E., André, F. E., & Desmyter, J. (1992) · Vaccine · doi:10.1016/0264-410x(92)90561-w · Cited by 29
Delem, A., Safary, A., Namur, F. D., Hauser, P., & D'Hondt, E. (1993) · Vaccine · doi:10.1016/0264-410x(93)90291-5 · Cited by 29
Vaccination against hepatitis A: comparison of different short-term immunization schedules
Jilg, W., Bittner, R., Bock, H. L., Clemens, R. L., Schätzl, H. M., Schmidt, M., André, F., & Deinhardt, F. (1992) · Vaccine · doi:10.1016/0264-410x(92)90565-2 · Cited by 24
Active immunization of homosexual men using a recombinant hepatitis B vaccine
Heß, G., Rossol, S., Voth, R., Cheatham‐Speth, D., Clemens, R. L., & Büschenfelde, K. M. Z. (1989) · Journal of Medical Virology · doi:10.1002/jmv.1890290402 · Cited by 19
Seroepidemiology of antibody to hepatitis A in the rural eastern part of Thailand.
Poovorawan, Y., Paiboonkasemsuthi, S., Theamboonlers, A., Kamolratanakul, P., & Chumdermpadetsuk, S. (1991) · PubMed · Cited by 16
Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine
Lorenz Theilmann, I., Kallinowski, B., Gmelin, K., Hofmann, F. M., Scheiermann, N., Wohland, B., Stickl, H., Maiwald, H., Moriabadi, F. K., Bock, H. L., et al. (1992) · Vaccine · doi:10.1016/0264-410x(92)90567-4 · Cited by 11
Increased risk of hepatitis A among female day-nursery workers in Belgium
Jacques, P., Moens, G. F. G., Damme, P. V., Goubau, P., Vranckx, R., STEENO, J., Muylle, L., & Desmyter, J. (1994) · Vaccine · doi:10.1016/0264-410x(94)90041-8 · Cited by 5
Aktive Immunisierung gegen Hepatitis A: Vergleich verschiedener Impfschemata
Müller, R., Bock, H. L., Clemens, R. L., & Jilg, W. (2008) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2008-1059431 · Cited by 5
Cited by
Sorted by citations
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Harpaz, R., Ortega‐Sanchez, I. R., & Seward, J. F. (2008) · Cited by 1,302
Fiore, A. E., Wasley, A., & Bell, B. P. (1999) · PsycEXTRA Dataset · doi:10.1037/e547812006-001 · Cited by 1,130
Rossio, J. L., Esser, M. T., Suryanarayana, K., Schneider, D. K., Bess, J. W., Vásquez, G. M., Wiltrout, T. A., Chertova, E. N., Grimes, M. K., Sattentau, Q. J., et al. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.7992-8001.1998 · Cited by 416
“Whole inactivated virions have been used successfully as vaccines for numerous viruses (16, 17, 41, 42, 46), but traditional means of viral inactivation can denature virion surface proteins.”
Vaccines to Prevent Viral Hepatitis
Lemon, S. M., & Thomas, D. L. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360307 · Cited by 332
Metadata
- Authors
- Clemens, R., Safary, A., Hepburn, A., Roche, C., Stanbury, W. J., & Andre, F. E.
- Corresponding author
- Clemens, R.
- ORCID
- Clemens, R.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-03-01
- Volume
- 171
- Issue
- Supplement 1
- Pages
- S44-S49
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2077738168
- Cited by
- 223
- References
- 23
- Citations by year
- 2025: 3 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 10 · 2012: 8
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis Viruses Studies and Epidemiology
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
- Keywords
- inactivated hepatitis A vaccine, vaccine safety, immunogenicity, seroconversion, antibody persistence, booster vaccination, vaccine-induced antibodies, hepatitis A prevention
- MeSH terms
- Adult, Child, Clinical Trials as Topic, Hepatitis A, Hepatitis Antibodies, Humans, Pilot Projects, Travel, Vaccines, Viral Hepatitis Vaccines, Vaccines, Inactivated, HIV Infections, Hepatitis A Virus, Human, Hepatitis A Vaccines, Hepatitis A Antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
